Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Janux Therapeutics Inc’s current trading price is -66.53% away from its 52-week high, while its distance from the 52-week low is 9.24%. The stock’s price range over this period has fluctuated between $21.97 and $71.71. The company, operating within the financial sector, had a trading volume of approximately 0.85 million for the day, which was noticeably higher than the average daily share volume of 0.84 million over the last 3 months.
Janux Therapeutics Inc (JANX) stock is currently valued at $24.0. During the last session, the stock experienced a remarkable rise, reaching $200.0 after opening at $24.0. The stock briefly dropped to $25.0 before ultimately closing at $24.87.
In terms of market performance, Janux Therapeutics Inc had a fairly uneven. The highest value for the stock in the past year was $71.71 on 12/05/24, and the lowest value was recorded at $21.97 on 08/11/25.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Janux Therapeutics Inc (JANX) has experienced a quarterly decline of -3.11% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.44B and boasts a workforce of 81 employees.
Janux Therapeutics Inc: What Analysts Are Saying
As of right now, 11 analysts are rating Janux Therapeutics Inc as a BUY, 3 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 25.83, with a change in price of -5.10. Similarly, Janux Therapeutics Inc recorded 934,036 in trading volume during the last 100 days, posting a change of -17.53%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for JANX stands at 0.02. Similarly, the long-term debt-to-equity ratio is also 0.02.
JANX Stock Stochastic Average
Today, Janux Therapeutics Inc’s raw stochastic average for the past 50 days stands at 31.61%, indicating a decline from the raw stochastic average of the last 20 days, which was 41.17%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 50.02% and 55.80% respectively.
JANX Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. Until today this year the stock’s price performance recorded a decrease of -44.73%. However, over the last six months, the performance has been stronger by -35.43%. The price of JANX decreased -9.30% over the last 30 days. And in the last five days, it has fallen by -3.88%.
